Company Overview and News

64
KLA-Tencor Set To Substantially Underperform Competition In 2018

2018-05-07 seekingalpha
KLA-Tencor recently reported its quarterly earnings and QoQ revenue growth was the lowest among a group of four competitors.
LRCX 0522 ORBK SSNLF ASMVF AMAT ASMVY 8035 TOELF KLAC TOELY

2
ASM INTERNATIONAL N.V. ANNOUNCES AVAILABILITY OF AGM MATERIALS

2018-04-16 globenewswire
ASM International N.V. (Euronext Amsterdam: ASM) today announces that the information regarding the Annual General Meeting of Shareholders (AGM) scheduled for May 28, 2018, is now available on the Company's website, www.asm.com. This information includes the convocation, the full agenda and annexes thereto. The U.S. market proxy materials for holders of New York Registry Shares are also posted on our website.
ASM 0522 ASMVF ASMVY

17
Kulicke And Soffa Industries Inc. (KLIC) - Significant Growth Opportunities

2018-03-18 valuewalkpremium
Finding profitable firms with strong growth opportunities and an undervalued stock price is becoming more difficult as the bull market carries on. We featured this stock as one of our top picks in our special June 2017 report “Selling Shovels in a Gold Rush,” and recent industry trends make the risk/reward tradeoff even more appealing. With impressive profitability and a significantly undervalued share price, Kulicke & Soffa Industries (KLIC:$23/share) earns a spot in January’s Most Attractive Stocks Model Portfolio and is this week’s Long Idea.
0522 AMKR TXN RTEC ASMVF KLIC ASMVY SPIL

22
Highly Profitable Tech Stock With Significant Growth Opportunities

2018-03-16 seekingalpha
Finding profitable firms with strong growth opportunities and an undervalued stock price is becoming more difficult.
0522 AMKR SSNLF TXN RTEC ASMVF ASMVY SPIL

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...